Drugmaker shares rise on swine-flu outbreak…

The swine flu outbreak boosted shares of makers of of flu treatments, vaccines and tests Monday.

Though Wall Street remains concerned that swine flu could put a damper on any global economic recovery, several companies could benefit.

Gilead Sciences Inc., Roche, GlaxoSmithKline and other companies with a stake in flu treatments and detection will likely see revenue boosts if the swine flu outbreak continues to spread, several Wall Street analysts said.

Gilead shares rose $1.86, or 4.1 percent, to $47.66 in afternoon trading.

Relenza, an inhaled drug, is made by GlaxoSmithKline, which saw U.S.-traded shares rise $2.41, or 8.2 percent, to $31.75 in afternoon trading.

Novavax shares nearly doubled in price to $2.84 in afternoon trading.
Read full article »»



Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s